SAB Biotherapeutics
SABS
26 hedge funds and large institutions have $65.9M invested in SAB Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.53% more ownership
Funds ownership: 0% → 4.53% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$6.87M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$6M |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$5.95M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$5.2M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.18M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $1K | +$1.3K | +13 | New |
|
SABS Hedge Fund Activity: Q1 2021 in Review
26 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2021, worth a combined $65.9M.
Buyers outnumbered sellers: 26 funds opened new SABS positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Basso Capital Management, opening a new position worth an estimated $6.87M.
- 26 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $65.9M of SAB Biotherapeutics stock for Q1 2021.
- 26 funds opened new SAB Biotherapeutics positions in Q1 2021 and 0 closed out, a net change of +26 holders.
- The largest SAB Biotherapeutics buyer in Q1 2021 was Basso Capital Management, an estimated $6.87M added.
Based on aggregated 13F filings for Q1 2021.